BioCentury
ARTICLE | Company News

Actelion, Asahi Kasei Corp. deal

April 23, 2007 7:00 AM UTC

ATLN ended a deal with Asahi to develop fasudil for pulmonary arterial hypertension (PAH) and angina for undisclosed reasons. ATLN gained rights to develop the Rho kinase inhibitor in North America a...